Overview

Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant

Status:
Completed
Trial end date:
2015-03-23
Target enrollment:
Participant gender:
Summary
Assess the pharmacokinetic profile of 2 doses of the XaraColl® implant after open laparotomy hernioplasty and assess the relative bioavailability of Xaracoll compared to a local bupivacaine infiltration.
Phase:
Phase 2
Details
Lead Sponsor:
Innocoll
Collaborator:
Premier Research Group plc
Treatments:
Bupivacaine